Article Text

P14 Pirfenidone is efficacious in patients with idiopathic pulmonary fibrosis (IPF) with more preserved lung function
  1. PW Noble1,
  2. WZ Bradford2,
  3. U Costabel3,
  4. I Glaspole4,
  5. MK Glassberg5,
  6. E Gorina2,
  7. D Kardatzke2,
  8. L Lancaster6,
  9. DJ Lederer7,
  10. SD Nathan8,
  11. C Pereira9,
  12. D Spirig10,
  13. JJ Swigris11,
  14. D Valeyre12,
  15. C Albera13
  1. 1Cedars-Sinai Medical Center, Los Angeles, California, USA
  2. 2InterMune, Inc. (A Wholly Owned Roche Subsidiary), Brisbane, California, USA
  3. 3Ruhrlandklinik and University of Duisburg—Essen, Essen, Germany
  4. 4Alfred Hospital, Melbourne, Australia
  5. 5University of Miami Miller School of Medicine, Miami, Florida, USA
  6. 6Vanderbilt University Medical Center, Nashville, Tennessee, USA
  7. 7Columbia University Medical Center, New York, New York, USA
  8. 8Inova Fairfax Hospital, Falls Church, Virginia, USA
  9. 9Paulista School of Medicine, Federal University of São Paulo, São Paulo, Brazil
  10. 10F. Hoffman-La Roche Ltd, Basel, Switzerland
  11. 11National Jewish Health, Denver, Colorado, USA
  12. 12Assistance Publique-Hôpitaux de Paris, Hôpital Avicenne, Bobigny, France
  13. 13University of Turin, Turin, Italy


Introduction and objectives IPF is a progressive, irreversible and fatal disease. Early treatment initiation when lung function is relatively preserved may have beneficial outcomes; however, published data to support this hypothesis are lacking. We investigated the efficacy of pirfenidone at 12 months in patients stratified by lung function using forced vital capacity (FVC) or GAP stage.

Methods Efficacy outcomes (FVC, 6-minute walk distance [6MWD] and dyspnea [UCSD SOBQ]) were analysed at 12 months in patients randomised to pirfenidone 2403 mg/d or placebo in the pooled CAPACITY/ASCEND population (N = 1247), stratified by baseline FVC (≥80%, <80%) and GAP stage (GAP I, GAP II-III). Treatment-by-subgroup interaction was tested based on a rank ANCOVA model. The factors in the model included study, region, treatment, subgroup and treatment-by-subgroup interaction term.

Results Demographic characteristics were similar across all four groups. In the placebo arm, disease progression as measured by FVC occurred with comparable frequency in patients with FVC ≥80% and FVC <80%, as well as in patients with GAP I and GAP II-III stage. A higher proportion of placebo patients with FVC <80% and GAP II-III stage had a ≥50-m decline in 6MWD or death or a ≥20-point change in the UCSD SOBQ total score. Pirfenidone treatment reduced the proportion of patients experiencing a ≥10% FVC decline or death and increased the proportion of patients with no FVC decline in all subgroups. Pirfenidone also reduced the proportion of patients with ≥50-m decline in the 6MWD or death and increased the proportion of patients with no 6MWD decline in all subgroups. The magnitude of treatment effect in patients with less vs more preserved lung function was comparable, with no significant treatment-by subgroup interaction (Figure 1).

Abstract P14 Figure 1

Treatment effect of pirfenidone by baseline lung function

Conclusions In the placebo population, clinically significant disease progression occurs in subgroups with more and less preserved lung function at baseline, underlying the need for early intervention. The magnitude of pirfenidone treatment effect on functional measures was comparable in these subgroups of patients (FVC <80% vs FVC ≥80% or GAP I vs GAP II-III stage), supporting the initiation of treatment soon after diagnosis, when pulmonary function is relatively preserved.

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.